Aliases & Classifications for Muscle Cancer

MalaCards integrated aliases for Muscle Cancer:

Name: Muscle Cancer 12 52 14
Myosarcoma 12 52 42 69
Malignant Neoplasm of Muscle 12 69
Malignant Tumor of the Muscle 12
Malignant Tumor of Muscle 12
Myomatous Neoplasm 69
Muscle Neoplasms 42


External Ids:

Disease Ontology 12 DOID:4045
ICD10 33 C49
NCIt 47 C4883

Summaries for Muscle Cancer

Disease Ontology : 12 A musculoskeletal system cancer that is located in muscle.

MalaCards based summary : Muscle Cancer, also known as myosarcoma, is related to skeletal muscle cancer and gallbladder leiomyoma, and has symptoms including muscle cramp, muscle rigidity and muscle spasticity. An important gene associated with Muscle Cancer is PAX3 (Paired Box 3), and among its related pathways/superpathways are Endometrial cancer and Transcriptional misregulation in cancer. The drugs Acetaminophen and Bupivacaine have been mentioned in the context of this disorder. Affiliated tissues include breast, lung and prostate, and related phenotypes are cellular and growth/size/body region

Wikipedia : 72 A soft-tissue sarcoma is a form of sarcoma that develops in connective tissue, though the term is... more...

Related Diseases for Muscle Cancer

Diseases related to Muscle Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 155)
id Related Disease Score Top Affiliating Genes
1 skeletal muscle cancer 11.9
2 gallbladder leiomyoma 10.9 MB PGR
3 myoma 10.9
4 blastema predominant kidney wilms' tumor 10.9 PGR TP53
5 marfanoid habitus-inguinal hernia-advanced bone age syndrome 10.9 DES KIT
6 lymphocytic infiltrate of jessner 10.9 DES PGR
7 central nervous system organ benign neoplasm 10.9 PGR TP53
8 bile duct rhabdomyosarcoma 10.9 KIT MYOD1
9 lung adenoma 10.8 PGR TP53
10 gigantism 10.8 DES MB
11 phagocyte bactericidal dysfunction 10.8 MB MYOG
12 pineal parenchymal tumor of intermediate differentiation 10.8 MYOD1 PAX3 PAX7
13 omphalocele 10.8 DES MYOD1
14 ovary rhabdomyosarcoma 10.8 DES PAX3
15 mannose-binding lectin protein deficiency 10.8 DES KIT PGR
16 liver angiosarcoma 10.8 DES KIT PGR
17 spleen cancer 10.8 DES MB MYOD1
18 mucinous ovarian cystadenoma 10.8 DES MB MYOD1
19 sebaceous adenoma 10.8 DES KIT PGR
20 fallopian tube benign neoplasm 10.7 CALD1 PGR
21 large cell acanthoma 10.7 DES KIT PGR
22 dartoic leiomyoma 10.7 CALD1 PGR
23 fibula aplasia complex brachydactyly 10.7 DES KIT PGR
24 gangliosidosis gm2 10.7 DES KIT PGR
25 rnase t2-deficient leukoencephalopathy 10.7 MDM2 TP53
26 breast myoepithelial neoplasm 10.7 PGR TP53
27 thyroiditis 10.7 CD34 PGR
28 colon neuroendocrine neoplasm 10.7 KIT PGR TP53
29 goiter, multinodular 1, with or without sertoli-leydig cell tumors 10.7 DES MB TP53
30 leiomyoma cutis 10.7 PGR TP53
31 bile duct sarcoma 10.7 MB MYOD1 MYOG
32 extragonadal nonseminomatous germ cell tumor 10.7 KIT PGR TP53
33 sarcoma 10.7 CREB3L2 KIT
34 intestinal perforation 10.6 PGR TP53
35 lateral medullary syndrome 10.6 MB MYOD1 MYOG
36 pineal region yolk sac tumor 10.6 DES PGR
37 appendix leiomyoma 10.6 CD34 KIT
38 small intestine leiomyosarcoma 10.6 CD34 KIT
39 acute cholinergic dysautonomia 10.6 MDM2 TP53
40 dystonia 10.6 CALD1 MYOG
41 rectum kaposi's sarcoma 10.6 KIT PGR TP53
42 retinal disease 10.6 KIT PGR TP53
43 paranasal sinus disease 10.6 CD34 PGR
44 prostatic acinar adenocarcinoma 10.6 PGR TP53
45 liver inflammatory pseudotumor 10.6 CD34 KIT
46 pleuropneumonia 10.6 CD34 PGR
47 secondary pulmonary hemosiderosis 10.6 DES MDM2 TP53
48 verruciform xanthoma of skin 10.6 CD34 PGR
49 multiple mucosal neuroma 10.6 CD34 TP53
50 primary pulmonary lymphoma 10.6 MDM2 MYOD1 MYOG

Graphical network of the top 20 diseases related to Muscle Cancer:

Diseases related to Muscle Cancer

Symptoms & Phenotypes for Muscle Cancer

UMLS symptoms related to Muscle Cancer:

muscle cramp, muscle rigidity, muscle spasticity, myoclonus, torticollis, muscle weakness, myalgia

MGI Mouse Phenotypes related to Muscle Cancer:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.33 CD34 DES FOXO1 GABPA KIDINS220 KIT
2 growth/size/body region MP:0005378 10.32 CREB3L2 FOXO1 GABPA KIDINS220 KIT MB
3 homeostasis/metabolism MP:0005376 10.29 CD34 DES FOXO1 GABPA KIT MB
4 mortality/aging MP:0010768 10.28 CREB3L2 DES FOXO1 GABPA KIDINS220 KIT
5 hematopoietic system MP:0005397 10.27 CD34 FOXO1 GABPA KIT MB MDM2
6 cardiovascular system MP:0005385 10.26 KIDINS220 KIT MB MDM2 MYOD1 PAX3
7 embryo MP:0005380 10.22 FOXO1 GABPA KIT MB MDM2 MYOG
8 muscle MP:0005369 10.15 DES FOXO1 GABPA KIT MB MDM2
9 craniofacial MP:0005382 10.14 TP53 CREB3L2 FOXO1 KIT MDM2 PAX3
10 integument MP:0010771 10.11 KIT MDM2 MYOG PAX3 PGR TFE3
11 no phenotypic analysis MP:0003012 10 GABPA KIDINS220 KIT MDM2 MYOD1 MYOG
12 limbs/digits/tail MP:0005371 9.98 CREB3L2 FOXO1 KIT MDM2 PAX3 PGR
13 neoplasm MP:0002006 9.97 CD34 FOXO1 KIT MDM2 MYOD1 PAX3
14 normal MP:0002873 9.9 TFE3 TP53 FOXO1 GABPA KIT MDM2
15 skeleton MP:0005390 9.36 CREB3L2 FOXO1 KIT MDM2 MYOD1 MYOG
16 pigmentation MP:0001186 9.35 KIT MDM2 PAX3 TFE3 TP53

Drugs & Therapeutics for Muscle Cancer

Drugs for Muscle Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 626)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Acetaminophen Approved Phase 4,Phase 1 103-90-2 1983
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2 2180-92-9, 38396-39-3 2474
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3 51-43-4 5816
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 57-27-2 5288826
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
8 Racepinephrine Approved Phase 4,Phase 2,Phase 3
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
Letrozole Approved, Investigational Phase 4,Phase 2,Phase 1 112809-51-5 3902
Benzocaine Approved Phase 4,Phase 3,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
Rocuronium Approved Phase 4,Phase 3 119302-91-9, 143558-00-3 441290
Levobupivacaine Approved Phase 4 27262-47-1 92253
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
Midazolam Approved, Illicit Phase 4,Early Phase 1 59467-70-8 4192
Acetylcholine Approved Phase 4,Phase 3,Phase 2 51-84-3 187
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 120511-73-1 2187
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
Etidronic acid Approved Phase 4 7414-83-7, 2809-21-4 3305
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53714-56-0 3911 657181
Darbepoetin alfa Approved, Investigational Phase 4 11096-26-7, 209810-58-2
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
Neostigmine Approved, Vet_approved Phase 4,Phase 3 59-99-4 4456
Desflurane Approved Phase 4 57041-67-5 42113
Ketamine Approved, Vet_approved Phase 4,Phase 3,Early Phase 1 6740-88-1 3821
Remifentanil Approved Phase 4 132875-61-7 60815
Metformin Approved Phase 4,Phase 2,Phase 1 657-24-9 14219 4091
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1 58-18-4 6010
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-22-0 6013
nivolumab Approved Phase 4,Phase 2,Phase 1 946414-94-4
33 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 1406-16-2
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2,Phase 1,Early Phase 1 50-14-6 5280793
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 2,Phase 1 67-97-0 6221 10883523 5280795
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
38 Cisatracurium Experimental Phase 4 96946-41-7
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
41 Adjuvants, Anesthesia Phase 4,Phase 3,Phase 2,Early Phase 1
42 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
44 Analgesics, Opioid Phase 4,Phase 3,Phase 2
45 Anesthetics Phase 4,Phase 3,Phase 2,Early Phase 1
46 Anesthetics, General Phase 4,Phase 3,Phase 2,Early Phase 1
47 Anesthetics, Intravenous Phase 4,Phase 3,Phase 2,Early Phase 1
48 Anesthetics, Local Phase 4,Phase 3,Phase 2
49 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1184)

id Name Status NCT ID Phase Drugs
1 Serratus Anterior Plane Block Versus Paravertebral Block for Postmastectomy Analgesia Unknown status NCT02103946 Phase 4
2 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4 doxorubicin, cytoxan
3 Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients Unknown status NCT00772824 Phase 4
4 Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace) Unknown status NCT01908556 Phase 4 Letrozole
5 Influence of Profound Muscle Relaxation on Muscle Trauma and Postoperative Pulmonary Function Unknown status NCT01804933 Phase 4 profound neuromuscular blockade
6 Quadratus Lumborum Block for Percutaneous Nephrostomy Unknown status NCT02121951 Phase 4 MAC
7 Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion Unknown status NCT00313066 Phase 4
8 Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes Completed NCT01223196 Phase 4 Pioglitazone;Placebo
9 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
10 Study to Monitor the Effects of Androgen Suppression Treatment on the Heart Completed NCT01230905 Phase 4
11 The Laparotomy Study Completed NCT02140593 Phase 4 Group STANDARD: Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment combined with saline infusion (placebo).;Group DEEP: Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level PTC 0-1 combined with bolus saline (placebo) mimicking standard treatment.
12 Prevention of Osteoporosis in Breast Cancer Survivors Completed NCT00567606 Phase 4
13 Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration Completed NCT01161563 Phase 4 Triptorelin pamoate;Leuprolide acetate
14 Comparison of Laryngeal Mask Airway (LMA®) and Tracheal Tube in Modified Radical Mastectomy on Breast Cancer Completed NCT00638599 Phase 4
15 The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery Completed NCT00122720 Phase 4 Darbepoetin Alfa
16 Deep Neuromuscular Relaxation in Patients for Thoraco-laparoscopic Esophagectomy Completed NCT02320734 Phase 4 Rocuronium
17 Myobloc Atrophy Study Completed NCT02052024 Phase 4 Botox;MYOBLOC
18 Breast Reconstruction With Acellular Dermal Matrix in the Setting of Breast Cancer Treatment Completed NCT02061527 Phase 4
19 The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway Completed NCT00755729 Phase 4
20 The Role of Vitamin D in Immune Function in Patients With Chronic Kidney Disease (CKD) Stages 3 and 4. Completed NCT00749736 Phase 4
21 Long-Term Lamivudine Therapy for Chronic Hepatitis B Completed NCT00120354 Phase 4
22 Investigation of Sugammadex in Outpatient Urological Procedures Recruiting NCT03138967 Phase 4 Rocuronium;Sugammadex;Neostigmine;Glycopyrrolate
23 Laser En Bloc Resection Of Bladder Tumor (HoLERBT) VS. Conventional Transurethral Resection Of Bladder Tumors (cTURBT) Recruiting NCT02555163 Phase 4
24 Ultrasound-Guided ONB for Transurethral Procedures - Interadductor Approach Recruiting NCT02696733 Phase 4 lidocaine 2%;0.9% Natrium Chloratum with a 2nd generation cephalosporin
25 Analgesic Effects of Ultrasound Guided PEC Blocks on Analgesic Opioid Consumption of Cancer Surgery Patients Recruiting NCT02495363 Phase 4 Bupivacaine 0.25-0.5%
26 Transitional Growth Hormone (GH) Use in Growth Hormone Deficient (GHD) Cancer Survivors Recruiting NCT02629926 Phase 4
27 The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction Recruiting NCT01427400 Phase 4 Botulinum Toxin-A;Saline
28 Effect Of Ketamine Infusion In Patients With COPD Applied One Lung Ventilation Recruiting NCT02962999 Phase 4 Ketamine;Saline
29 Seroma Reduction After Mastectomy Recruiting NCT03305757 Phase 4 Artiss
30 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Recruiting NCT02959853 Phase 4 Anastrazole
31 Metformin Induces a Dietary Restriction-like State in Human Recruiting NCT02745886 Phase 4 metformin 0.85 twice daily for 6 months
32 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Recruiting NCT02982954 Phase 4 Nivolumab;Ipilimumab
33 Sitagliptin and Brown Adipose Tissue Recruiting NCT02294084 Phase 4 Sitagliptin;placebo
34 The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies Active, not recruiting NCT01552291 Phase 4 Placebo
35 Levobupivacaine and Lidocaine for Paravertebral Block Causes Greater Hemodynamic Oscillations Than Levobupivacaine Active, not recruiting NCT02004834 Phase 4 levobupivacaine
36 "En Bloc" Resection of NMIBC: a Prospective, Single Centre,Randomized Study Not yet recruiting NCT03221062 Phase 4
37 Neuromuscular Blockade on Shoulder Pain of Elderly Not yet recruiting NCT03210376 Phase 4 Deep Neuromuscular Blockade (NMB);Moderate Neuromuscular Blockade (NMB);Sugammadex;Neostigmine
38 Local Anesthetic for Total Mastectomy Surgery Not yet recruiting NCT02893384 Phase 4 Local Anesthetic Injection above the serratus anterior
39 Use of Nesiritide in the Management of Acute Diastolic Heart Failure Terminated NCT00083772 Phase 4 Nesiritide
40 Testosterone and Pain Sensitivity Withdrawn NCT01689896 Phase 4 Testosterone Gel;Placebo Gel
41 Effect of EPA on Aerobic Performance, Muscle, and Quality of Life in Colorectal Cancer Surgery Patients Unknown status NCT01320319 Phase 2, Phase 3
42 Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
43 Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer Unknown status NCT00867347 Phase 3
44 Short Term Outcomes of Laparoscopic Intersphincteric Resection for Low Rectal Cancer Unknown status NCT01836926 Phase 2, Phase 3
45 Clinical Trial Using Bipolar Technology for Transurethral Resection of Bladder Tumor Unknown status NCT01581723 Phase 3
46 Pelvic Floor Rehabilitation for Gynecological Cancer Patients Unknown status NCT01871688 Phase 2, Phase 3
47 Cognitive Behavioral Therapy (CBT) and Physical Exercise for Climacteric Symptoms in Breast Cancer Patients Experiencing Treatment-Induced Menopause: a Multicenter Randomized Trial Unknown status NCT00582244 Phase 3
48 Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study Unknown status NCT01509781 Phase 3
49 Esophagectomy Associated Respiratory Complications: Ivor-Lewis Versus Sweet Approaches Unknown status NCT01053182 Phase 3
50 Proton Magnetic Resonance Spectroscopy (1H MRS) in Evaluating the Bone Marrow, Muscle and Adipose Tissue on Normal and Human Immunodeficiency Virus Infected Subjects Unknown status NCT00172315 Phase 3

Search NIH Clinical Center for Muscle Cancer

Cochrane evidence based reviews: myosarcoma

Genetic Tests for Muscle Cancer

Anatomical Context for Muscle Cancer

MalaCards organs/tissues related to Muscle Cancer:

Breast, Lung, Prostate, Bone, Skeletal Muscle, Testes, Uterus

Publications for Muscle Cancer

Articles related to Muscle Cancer:

id Title Authors Year
Cytotoxicity Studies of the Extracts, Fractions, and Isolated Compound of Pseudocedrela kotschyi on Cervical Cancer (HeLa), Breast Cancer (MCF-7) and Skeletal Muscle Cancer (RD) Cells. ( 28250653 )
YAPping about differentiation therapy in muscle cancer. ( 25117705 )
The not-so-skinny on muscle cancer. ( 23079652 )
Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. ( 20193046 )
A new model for muscle cancer. ( 17585343 )

Variations for Muscle Cancer

Expression for Muscle Cancer

Search GEO for disease gene expression data for Muscle Cancer.

Pathways for Muscle Cancer

GO Terms for Muscle Cancer

Cellular components related to Muscle Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.77 ASPSCR1 CREB3L2 EWSR1 FOXO1 GABPA MDM2
2 nucleoplasm GO:0005654 9.36 ASPSCR1 CREB3L2 FOXO1 GABPA MDM2 MYOD1

Biological processes related to Muscle Cancer according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 regulation of transcription from RNA polymerase II promoter GO:0006357 9.93 FOXO1 GABPA KIT MYOD1 PAX3
2 transcription, DNA-templated GO:0006351 9.9 CREB3L2 EWSR1 FOXO1 GABPA MYOD1 MYOG
3 positive regulation of gene expression GO:0010628 9.89 CD34 GABPA KIT MDM2 TP53
4 transcription from RNA polymerase II promoter GO:0006366 9.88 CREB3L2 GABPA MYOD1 PAX3 TFE3 TP53
5 skeletal muscle tissue development GO:0007519 9.61 MYOD1 MYOG PAX7
6 muscle organ development GO:0007517 9.56 MYOD1 MYOG PAX3 PAX7
7 myotube differentiation GO:0014902 9.52 MYOD1 MYOG
8 positive regulation of skeletal muscle fiber development GO:0048743 9.51 MYOD1 MYOG
9 positive regulation of transcription, DNA-templated GO:0045893 9.5 CREB3L2 FOXO1 MYOD1 MYOG PAX3 TFE3
10 muscle cell fate commitment GO:0042693 9.48 MYOD1 MYOG
11 paracrine signaling GO:0038001 9.46 CD34 PGR
12 cellular response to actinomycin D GO:0072717 9.37 MDM2 TP53
13 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.32 CREB3L2 FOXO1 GABPA MYOD1 MYOG PAX3
14 regulation of transcription, DNA-templated GO:0006355 10.06 CREB3L2 EWSR1 FOXO1 GABPA MYOD1 MYOG

Molecular functions related to Muscle Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription regulatory region DNA binding GO:0044212 9.71 CREB3L2 GABPA TFE3 TP53
2 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001077 9.65 CREB3L2 GABPA MYOG PGR TFE3
3 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000978 9.63 CREB3L2 GABPA MYOD1 MYOG PGR TFE3
4 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0001228 9.62 GABPA MYOD1 MYOG TP53
5 sequence-specific DNA binding GO:0043565 9.5 FOXO1 GABPA MYOD1 MYOG PAX3 PAX7
6 transcription factor activity, sequence-specific DNA binding GO:0003700 9.32 CREB3L2 FOXO1 GABPA MYOD1 MYOG PAX3
7 DNA binding GO:0003677 10.02 CREB3L2 FOXO1 GABPA MYOD1 MYOG PAX7

Sources for Muscle Cancer

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....